Particle.news
Download on the App Store

JAMA Study Links New York Medical Cannabis Program to Reduced Opioid Use

An 18‑month patient‑level analysis documented sustained declines in prescribed morphine‑equivalent doses among chronic pain patients.

Overview

  • Researchers at Albert Einstein College of Medicine and Montefiore tracked 204 adults newly certified for New York’s Medical Cannabis Program between September 2018 and July 2023 using state prescription records.
  • Average daily opioid dose fell from 73.3 mg to 57 mg morphine‑equivalent over 18 months, a 22% reduction.
  • In months when participants received a 30‑day cannabis supply, their opioid use was 3.5 mg morphine‑equivalent per day lower than months without cannabis.
  • Authors say the findings support a pharmacist‑supervised, medicalized model for dispensing cannabis in pain management.
  • The observational study, published in JAMA Internal Medicine, provides patient‑level evidence but does not establish causality or broad generalizability.